Gregory Perry
Director of Finance/CFO bei MERUS N.V.
Vermögen: - $ am 31.03.2024
Profil
Gregory D.
Perry is currently an Independent Director at KALA BIO, Inc. since 2018 and the Chief Financial Officer at Merus NV since 2016.
Previously, he served as an Independent Director at Astellas Institute for Regenerative Medicine from 2011 to 2016.
He was also a Director at rEVO Biologics, Inc. in 2014.
From 2009 to 2013, he held the positions of Chief Financial Officer, Treasurer & Executive VP at ImmunoGen, Inc. He was the Chief Financial Officer & Senior Vice President at Transkaryotic Therapies, Inc. from 2003 to 2005.
Additionally, he served as the SVP-Finance, Business Development & Life Sciences at Revvity, Inc. He was the Chief Financial Officer at Domantis Ltd.
in 2006.
In 2015, he served as the Chief Financial & Administrative Officer at Aegerion Pharmaceuticals, Inc. He also held the position of Chief Financial Officer & Vice President at GE Medical Systems, Inc. Furthermore, he was the Chief Financial Officer & Executive Vice President at Elixir Pharmaceuticals, Inc. from 2007 to 2008.
He served as the Chief Financial & Business Officer at Sesen Bio, Inc. from 2014 to 2015.
He was the Chief Financial Officer at Invivo Therapeutics Holdings Corp.
in 2013.
He served as the Chief Financial & Administrative Officer at Novelion Therapeutics, Inc. in 2016 and the Chief Financial Officer at Finch Therapeutics Group, Inc. from 2018 to 2022.
Mr. Perry obtained his undergraduate degree from Amherst College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
MERUS N.V.
-.--% | 14.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Gregory Perry
| Unternehmen | Position | Beginn |
|---|---|---|
| MERUS N.V. | Director of Finance/CFO | 14.06.2023 |
| KALA BIO, INC. | Director/Board Member | 05.03.2018 |
Ehemalige bekannte Positionen von Gregory Perry
| Unternehmen | Position | Ende |
|---|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Director of Finance/CFO | 30.04.2022 |
| NOVELION THERAPEUTICS INC. | Director of Finance/CFO | 31.12.2017 |
| AEGERION PHARMACEUTICALS, INC. | Director of Finance/CFO | 01.11.2016 |
| OCATA THERAPEUTICS INC | Director/Board Member | 10.02.2016 |
| CARISMA THERAPEUTICS, INC. | Director of Finance/CFO | 01.06.2015 |
Ausbildung von Gregory Perry
| Amherst College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 6 |
|---|---|
| IMMUNOGEN, INC. | Health Technology |
| REVVITY, INC. | Health Technology |
| KALA BIO, INC. | Health Technology |
| MERUS N.V. | Health Technology |
| INVIVO THERAPEUTICS HOLDINGS CORP. | Health Technology |
| FINCH THERAPEUTICS GROUP, INC. | Health Services |
| Private Unternehmen | 9 |
|---|---|
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
Domantis Ltd.
 Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | Health Technology |
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
GE Medical Systems, Inc.
 GE Medical Systems, Inc. Medical SpecialtiesHealth Technology GE Medical Systems was a manufacturer of diagnostic imaging and medical monitoring systems. It used to provide information technology services to health care providers. The company was headquartered in Waukesha, WI. | Health Technology |
Elixir Pharmaceuticals, Inc.
 Elixir Pharmaceuticals, Inc. Investment Trusts/Mutual FundsMiscellaneous Elixir Pharmaceuticals, Inc. operates as a holding company with interest in manufacturing and developing biopharmaceutical products for the treatment of metabolic diseases such as diabetes and obesity. The company was founded by Leonard Guarente, Cynthia J. Kenyon, Cindy Bayley, Louis Kunkel, Annibale Puca, and Thomas Perls in 1999 and is headquartered in Cambridge, MA. | Miscellaneous |
Astellas Institute for Regenerative Medicine
 Astellas Institute for Regenerative Medicine Pharmaceuticals: MajorHealth Technology Astellas Institute for Regenerative Medicine engages in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
rEVO Biologics, Inc.
 rEVO Biologics, Inc. BiotechnologyHealth Technology rEVO Biologics, Inc. engages in the development and commercialization of specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions. Its products include ATryn, which prevents blood clots during and after surgery and childbirth for patients with hereditary antithrombin deficiency. The company was founded in February 1993 and is headquartered in Framingham, MA. | Health Technology |
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelion Therapeutics, Inc. engaged in the development and commercialization of pharmaceuitical products. It focused in providing new standards of care for individuals living with rare diseases. The company was founded on February 3, 1981 and was headquartered in Vancouver, Canada. | Health Technology |
